Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities

Fig. 5

Effects of YL529 on tumor growth, lung and lymph node metastasis in muscle model. The muscle metastasis models were treated with YL529 or controls orally. a YL529 resulting in significant tumor growth inhibition; b There was no significant difference of body weight after YL529 treated; c and d Percentage of mice with lung and lymph node metastasis; e Mean volume of auxiliary lymph nodes were harvested from mice. Mean ± SEM, n = 10, *p < 0.05, **p < 0.01

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us